Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Conditions
Recurrent Diffuse Large B-Cell Lymphoma · Recurrent Grade 3b Follicular Lymphoma · Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements · Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements · Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified · Recurrent Primary Mediastinal Large B-Cell Lymphoma · Recurrent Transformed Non-Hodgkin Lymphoma · Refractory Diffuse Large B-Cell Lymphoma · Refractory Grade 3b Follicular Lymphoma · Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements · Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements · Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified · Refractory Primary Mediastinal Large B-Cell Lymphoma · Refractory Transformed Non-Hodgkin Lymphoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States
Contact: Principal Investigator (Marie Hu)Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Contact: Principal Investigator (Yazeed Sawalha)
Study leads
Yazeed Sawalha
Principal Investigator
Ohio State University Comprehensive Cancer Center